Literature DB >> 21936705

Maintenance of human embryonic stem cells in mesenchymal stem cell-conditioned media augments hematopoietic specification.

Verónica Ramos-Mejía1, Agustín F Fernández, Verónica Ayllón, Pedro J Real, Clara Bueno, Per Anderson, Francisco Martín, Mario F Fraga, Pablo Menendez.   

Abstract

The realization of human embryonic stem cells (hESC) as a model for human developmental hematopoiesis and in potential cell replacement strategies relies on an improved understanding of the extrinsic and intrinsic factors regulating hematopoietic-specific hESC differentiation. Human mesenchymal stem cells (hMSCs) are multipotent cells of mesodermal origin that form a part of hematopoietic stem cell niches and have an important role in the regulation of hematopoiesis through production of secreted factors and/or cell-to-cell interactions. We have previously shown that hESCs may be successfully maintained feeder free using hMSC-conditioned media (MSC-CM). Here, we hypothesized that hESCs maintained in MSC-CM may be more prone to differentiation toward hematopoietic lineage than hESCs grown in standard human foreskin fibroblast-conditioned media. We report that specification into hemogenic progenitors and subsequent hematopoietic differentiation and clonogenic progenitor capacity is robustly enhanced in hESC lines maintained in MSC-CM. Interestingly, co-culture of hESCs on hMSCs fully abrogates hematopoietic specification of hESCs, thus suggesting that the improved hematopoietic differentiation is mediated by MSC-secreted factors rather than by MSC-hESC physical interactions. To investigate the molecular mechanism involved in this process, we analyzed global (LINE-1) methylation and genome-wide promoter DNA methylation. hESCs grown in MSC-CM showed a decrease of 17% in global DNA methylation and a promoter DNA methylation signature consisting of 45 genes commonly hypomethylated and 102 genes frequently hypermethylated. Our data indicate that maintenance of hESCs in MSC-CM robustly augments hematopoietic specification and that the process seems mediated by MSC-secreted factors conferring a DNA methylation signature to undifferentiated hESCs which may influence further predisposition toward hematopoietic specification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936705     DOI: 10.1089/scd.2011.0400

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  15 in total

1.  Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα.

Authors:  C Bueno; J L Sardina; B Di Stefano; D Romero-Moya; A Muñoz-López; L Ariza; M C Chillón; A Balanzategui; J Castaño; A Herreros; M F Fraga; A Fernández; I Granada; O Quintana-Bustamante; J C Segovia; K Nishimura; M Ohtaka; M Nakanishi; T Graf; P Menendez
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

2.  Influence of activin A supplementation during human embryonic stem cell derivation on germ cell differentiation potential.

Authors:  Galbha Duggal; Björn Heindryckx; Sharat Warrier; Thomas O'Leary; Margot Van der Jeught; Sylvie Lierman; Liesbeth Vossaert; Tom Deroo; Dieter Deforce; Susana M Chuva de Sousa Lopes; Petra De Sutter
Journal:  Stem Cells Dev       Date:  2013-08-14       Impact factor: 3.272

3.  Efficient derivation and genetic modifications of human pluripotent stem cells on engineered human feeder cell lines.

Authors:  Chunlin Zou; Bin-Kuan Chou; Sarah N Dowey; Kitman Tsang; Xiaosong Huang; Cyndi F Liu; Cory Smith; Jonathan Yen; Prashant Mali; Yu Alex Zhang; Linzhao Cheng; Zhaohui Ye
Journal:  Stem Cells Dev       Date:  2012-02-15       Impact factor: 3.272

4.  The Notch ligand DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate.

Authors:  V Ayllón; C Bueno; V Ramos-Mejía; O Navarro-Montero; C Prieto; P J Real; T Romero; M J García-León; M L Toribio; A Bigas; P Menendez
Journal:  Leukemia       Date:  2015-03-17       Impact factor: 11.528

5.  The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations.

Authors:  Carlos A Ribeiro; Joana S Fraga; Mário Grãos; Nuno M Neves; Rui L Reis; Jeffrey M Gimble; Nuno Sousa; António J Salgado
Journal:  Stem Cell Res Ther       Date:  2012-05-02       Impact factor: 6.832

6.  Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors.

Authors:  Verónica Ramos-Mejía; Rosa Montes; Clara Bueno; Verónica Ayllón; Pedro J Real; René Rodríguez; Pablo Menendez
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

7.  Specific marking of hESCs-derived hematopoietic lineage by WAS-promoter driven lentiviral vectors.

Authors:  Pilar Muñoz; Miguel G Toscano; Pedro J Real; Karim Benabdellah; Marién Cobo; Clara Bueno; Verónica Ramos-Mejía; Pablo Menendez; Per Anderson; Francisco Martín
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

8.  DNA methylation age of human tissues and cell types.

Authors:  Steve Horvath
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

9.  Absence of WASp Enhances Hematopoietic and Megakaryocytic Differentiation in a Human Embryonic Stem Cell Model.

Authors:  Miguel G Toscano; Pilar Muñoz; Almudena Sánchez-Gilabert; Marién Cobo; Karim Benabdellah; Per Anderson; Verónica Ramos-Mejía; Pedro J Real; Olaf Neth; Agueda Molinos-Quintana; Philip D Gregory; Michael C Holmes; Francisco Martin
Journal:  Mol Ther       Date:  2015-10-27       Impact factor: 11.454

10.  A synthetic three-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells.

Authors:  Yulin Xu; Wei Shan; Xia Li; Binsheng Wang; Senquan Liu; Yebo Wang; Yan Long; Ruxiu Tie; Limengmeng Wang; Shuyang Cai; Hao Zhang; Yu Lin; Mingming Zhang; Weiyan Zheng; Yi Luo; Xiaohong Yu; Jiing-Kuan Yee; Junfeng Ji; He Huang
Journal:  J Hematol Oncol       Date:  2016-09-29       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.